secwatch.observer — SEC 8-K summary
======================================

Issuer:     Skye Bioscience, Inc. (SKYE)
CIK:        0001516551
Form:       8-K
Filed at:   2023-02-16T23:59:59+00:00
Accession:  0001516551-23-000020
Event type: leadership
Sentiment:  positive
Materiality: 0.55
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Skye Bioscience appoints Dr. Deborah Charych to Board of Directors; director Rai resigns
--------------------------------------------------------------------------------

- Bobby Rai resigned from Board and Nominating Committee effective Feb 14, 2023; not due to any disagreement.
- Dr. Deborah Charych elected to fill the vacancy; will receive $40,000 annual cash compensation.
- Charych granted options to purchase 250,000 shares, vesting monthly over one year.
- Charych co-founded RayzeBio, led R&D strategy raising $418M; previously led Nektar deal with Bristol Myers for $1.8B.
- Her background includes GPCR and cannabinoid receptor biology, relevant to Skye's glaucoma drug development.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000020/0001516551-23-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1516551/000151655123000020/skye-20230214.htm
  HTML page:      https://secwatch.observer/filing/0001516551-23-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer